BACKGROUND: The American Society of Clinical Oncology Quality Oncology Practice Initiative endorses in their core measures that providers should discuss the goals of care (GOC) at the time of chemotherapy consent. GOC refers to chemotherapy treatment intent: cure versus noncure. In this study, the authors sought to determine whether attributes of patients and initial patient-physician encounters were associated with patients' understanding of their GOC. METHODS: In total, the authors surveyed 125 consecutive, newly diagnosed patients who were receiving chemotherapy for solid malignancies at a single academic cancer center and performed a medical record review for additional data. Patient understanding of their oncologist's GOC and oncologist's reported GOC were compared. The primary outcome was concordance of patient-physician dyads regarding the GOC (cure vs noncure). RESULTS: One hundred twenty-five of 137 of eligible patients (91%) completed the survey. Only 95 of 125 patient-physician pairs (75%) patient-physician pairs were concordant regarding the GOC. In a multivariable logistic regression, both older patients (odds ratio, 0.21; 95% confidence interval, 0.08-0.57) and non-native English speakers had an almost 80% lower odds (odds ratio, 0.23; 95% confidence interval, 0.05-0.93) of GOC concordance compared with younger patients and native English speakers. Patients who received printed chemotherapy information during the patient-physician consent process had almost 3 times greater odds (odds ratio, 2.88; 95% confidence interval, 1.24-6.68) of GOC concordance with their physician compared with those who did not receive materials. CONCLUSIONS: Patient misunderstanding of GOC was substantial, with 25% of cancer patients misunderstanding the goal of their chemotherapy treatment. Key predictors of GOC misunderstanding included factors that potentially were amenable to interventions at the time of chemotherapy consent. Cancer 2013;119:691-9.
INTRODUCTION
A consent form, signed and dated by both the patient and their treating physician, that details the chemotherapy drugs and their potential toxicities is a requirement at most medical centers. This form is intended to document the conversation between patient and oncologist and to demonstrate that the patient was informed of their treatment options, the expected risks, and the potential benefits of the treatment they are agreeing to receive. Prior research suggests that patients and physicians may differ in their understanding of the intent of chemotherapy or goals of care (GOC). [1] [2] [3] Misperceptions of prognosis or GOC are important to recognize, because they may lead to requests for ineffective or futile medical care. [4] [5] [6] An accurate understanding of GOC may lead to patients making more informed treatment decisions that are aligned with their overall goals and avoid costly treatments at the end of life. [7] [8] [9] [10] Inherent in the GOC discussion before chemotherapy is a discussion of the cancer diagnosis, prognosis, and treatment options. Discussing prognosis with patients can be a difficult undertaking, and there are several reasons why physicians may not discuss prognosis. Physicians may fear that they will increase patient distress or cause a patient to lose hope. 11 Alternatively, if a discussion regarding prognosis occurs, then there is also the possibility that the physician discloses overly optimistic information. 4, [12] [13] [14] [15] Prior research indicates that approximately 33% of patients who receive treatment for incurable cancer overestimate their prognoses compared with their physicians. 4, 7, 16 We examined cancer patient-physician dyads to measure concordance in understanding the GOC of chemotherapy. We dichotomized GOC into 2 categories-curative and non-curative-and focused on patients' understanding of the GOC at initiation of chemotherapy to determine whether patient attributes and components of the initial patient-physician encounters were associated with subsequent patient-physician GOC concordance. 
MATERIALS AND METHODS
We sampled all consecutive, newly diagnosed patients who received their first course of intravenous chemotherapy for a solid malignancy at Massachusetts General Hospital (MGH) between December 17, 2008 and February 23, 2009 . Patients were screened for eligibility using the new patient appointment lists in the Massachusetts General Hospital chemotherapy infusion suite. All stages of disease (stages I-IV) were eligible for participation. Patients were required to be able to read and speak English. Patients also were required to have participated in the consent discussion for chemotherapy within the previous 30 days, and patients could not be enrolled on a clinical trial.
Eligible patients were approached by a member of the research staff during their chemotherapy appointment and were invited to participate in the study. The patients provided verbal consent for the study, which included completion of the survey and a review of their medical records. Consenting patients were provided the survey to complete during their chemotherapy infusion. Data collected from the medical record included age, sex, disease site, stage, histology, reason(s) for ineligibility, provider name, and the provider's GOC. This study was approved by the institutional review board at Dana-Farber/Harvard Cancer Center.
Survey Instrument
The 24-item survey (Appendix A) was designed to assess patient understanding of the goal of their chemotherapy treatment and to measure several areas that are relevant to this understanding. The domains of interest addressed by the patient survey included: 1) social support, 2) diagnosis, 3) prognosis, 4) treatment goals, 5) information preferences, 6) psychological distress, and 7) chemotherapy consent. Items addressing these domains were included from previously validated surveys. 11, [17] [18] [19] [20] The survey also asked patients to describe their demographics and functional status, and the survey included questions addressing the details of the patients' consent conversations with their treating physicians. The survey consisted of primarily close-ended questions with multiple response options. Most questions included the option other through which patients could express responses that were not among those listed. The survey was piloted on a sample of 10 patients.
Outcome Variables
The key outcome variable in the analyses was patient-physician concordance regarding the oncologist's treatment intent (curative vs non-curative). To determine patients' understanding of their oncologists' goals of chemotherapy treatment, the survey included the following question: ''What did your oncologist explain the purpose of your chemotherapy to be? (please check all that apply).'' Response options were as follows: 1) decrease the chance the disease will return, also called adjuvant treatment; 2) provide a prolonged time without any evidence of disease, also called cure; 3) control the growth of the cancer without getting rid of it completely to prolong life; and 4) reduce side effects and symptoms of the cancer to promote your comfort, also called palliation. We coded positive responses to options 1 and/or 2 as curative and coded positive responses to options 3 and/or 4 as non-curative. If the respondent checked the last option in combination with either the first or the second response options, then the response was categorized as curative. If the respondent checked the third option with either the first or the second response options, then the response was categorized as confused, because the patient indicated that the goal of chemotherapy treatment was both cure and non-cure.
To determine the physicians' goals of chemotherapy treatment for each patient in the study, we reviewed the Massachusetts General Hospital chemotherapy order entry system. The chemotherapy order entry, as part of the process of writing orders for chemotherapy, requires physicians to answer several questions regarding the patient (eg, patient height and weight, tumor site, treatment regimen) before they can write chemotherapy orders. One such question asks physician to indicate whether the chemotherapy regimen is being administered for either adjuvant/neoadjuvant/curative intent or palliative/metastatic intent. In this analysis, palliative/metastatic intent was coded as non-curative. If a patient and their physician indicated the same GOC, then we termed this result concordant. If a patient and their physician indicated a different GOC, then we termed this result non-concordant. Within the non-concordant category, the results were subdivided into patients who were more optimistic than the physician (ie, the patient indicated curative intent, and the physician indicated non-curative intent) and patients who were less optimistic than the physician (ie, the patient indicated non-curative intent, and the physician indicated curative intent).
Predictor Variables
Hypotheses drove the selection of the majority of predictor variables we studied and were defined a priori. Predictor variables included distress level (from the National Comprehension Cancer Network Distress Thermometer on the patient survey 20 ), English as a second language, provision of printed information on chemotherapy (measured by the patient reporting whether or not they received printed handouts explaining the role and intent of their chemotherapy drugs), and whether the patient was alone at the time of the consent discussion. In addition, given the possibility that 1) physician communication style may vary according to their cancer subspecialty (eg, breast cancer specialists may communicate GOC differently than lung cancer specialists) and 2) each physician was a member of only 1 subspecialty group, patient tumor site (as a measure of physician specialty) also was considered among the possible predictor variables. Standard demographic variables (ie, age, sex, race, education level) also were included among predictor variables as well as tumor stage.
Statistical Analysis
We determined measures of central tendency for all covariates and for the outcome variable. In bivariate analyses, we compared the cohorts' covariates with the outcome variable to determine associations. Associations between categoric variables were determined using chi-square tests, and associations between categoric and continuous variables were determined using t tests. Multivariable logistic regression described associations between predictor variables and the outcome variable. We estimated variance using the robust method (also known as the Huber/ White/sandwich method) 21, 22 for clustered-correlated data; because, with this method, multiple patients can be nested or clustered within a smaller number of providers. 23 All analyses were done using the STATA statistical software package (version 11.2; Stata Corporation, College Station, Tex).
RESULTS
In total, 268 consecutive patients were screened for the study; of these, 137 patients were eligible, and 125 consented to participate (response rate, 91%) ( Fig. 1) . The predominant reasons for patient ineligibility included non-chemotherapy treatment (eg, blood transfusion; N ¼ 36), enrollment on a clinical trial (N ¼ 20), and treatment with second-line (or higher) therapies (N ¼ 17). Table 1 lists the baseline characteristics of all participants. The mean patient age was 62 years, and 38% were aged 65 years, 42% were men, 58% were women, 9% were nonwhite, and 12% indicated that English was their second language (however, they were able to read and write in English without an interpreter and, thus, were eligible for the study). In addition, 68% of patients reported at least a college education, and the mean distress score (on a scale from 0 to 10) for the sample on the day of survey was 4.31. Of the patient-physician dyads, 76% (95 of 125) were concordant, and 24% (30 of 125) were discordant regarding GOC. The kappa coefficient was 0.44, indicating moderate agreement between patients and their physicians on this matter. 24 Of the patient-physician dyads that were concordant (n ¼ 95), the goal of treatment was curative 99% (94 of 95) of the time and non-curative 1% (1 of 95) of the time. Of the patient-physician dyads that were discordant (n ¼ 30), 20 of 30 patients (66%) reported that their physician was treating them with curative intent, but their physicians reported that the intent was non-curative. In the remaining patients, 10 of 30 patients (33%) reported that their physician was treating them with non-curative intent, but their physicians reported that the intent was curative.
Bivariate analysis (Table 2 ) demonstrated a strong association between GOC concordance and patient age. Concordant patients tended to be younger than non-concordant patients (mean age, 60 years vs 66 years; P ¼ .02). In addition, 6 of 15 participants (40%) who spoke English as a second language were discordant regarding GOC, which was approximately twice the rate (24 of 110 participants; 22%) among of native English speakers (P ¼ .12).
The concordant and non-concordant groups did not vary with respect to sex, race, education, or distress level; nor did they vary with respect to patients' cancer site or disease stage (results not shown).
In the multivariable logistic regression model (Table 3) , 3 predictors of concordance emerged as both clinically and statistically significant. Patients aged 65 years had almost 80% lower odds (odds ratio, 0.21; P ¼ .01) of concordance compared with patients aged <65 years. Patients who spoke English as a second language had an almost 80% lower odds (odds ratio, 0.23; P ¼ .04) of concordance compared with patients who were native English speakers. Finally, the patients who reported receiving printed chemotherapy education materials at the time of chemotherapy consent had almost 3 times the odds (odds ratio, 2.88; P ¼ .01) of concordance compared with those who did not report receiving the materials.
DISCUSSION
The current investigation demonstrates that the concordance of patient-physician dyads regarding GOC was the same in only 76% of cases and that 30 of 125 patients (24%) did not appear to understand what the chemotherapy they were receiving was intended to do for their illness. Of these patients, most believed that their physician was treating them for cure, whereas their physicians' stated intent was not curative. This finding resonates with previously published reports of discordance of physician-patient dyads on the matter of prognosis among cancer patients, in whom it has been demonstrated that 33% of patients with advanced cancer hold more optimistic survival expectations (ie, prognoses) than their physicians. 2, 7, 12 The current work extends the existing literature on cancer patients' understanding of their illness by identifying yet another index of patient cancer care (ie, treatment goals) in which there appears to be patient misunderstanding (generally optimistic) regarding their illness. We observed that approximately 25% of patients did not appear to understand the goals of the potentially toxic chemotherapy they were receiving. Patient and physician clarity at the time of treatment decision-making regarding GOC is of critical importance given that misunderstandings like these have the potential to lead to future requests for more intense, but often futile, chemotherapy. [4] [5] [6] Although some of the non-concordance regarding GOC in the incurable population may be attributed to unrealistic optimism, 24 the quality of the pretreatment patient-physician discussions likely also have an impact on this measure. At least 2 of our findings suggest that physician-patient communication may explain some of the discrepancy in GOC understanding between patients and physicians. That is: 1) non-native English speakers were less likely than native English speakers to share their physicians' understanding of their chemotherapy treatment intent, and 2) those patients who received printed material were more likely to understand their physicians' treatment intent. These findings point to potentially amenable aspects of the patient-physician encounter that may lead to a better understanding of GOC, including communication aids targeted at elderly and non-native English-speaking patients and the provision of printed information material at the time of the chemotherapy consent process.
A signed patient consent for chemotherapy is an American Society of Clinical Oncology Quality Oncology Practice Initiative measure 25 and is intended to be a proxy for an open, honest, and informative conversation between provider and patient that includes all information (including GOC) needed for a patient to understand relevant treatment possibilities and their potential outcomes. 26, 27 Misunderstanding the GOC (eg, curative vs non-curative) may lead patients to make treatment decisions they otherwise would not have made. 28 The 20 of 125 patients in our study who erroneously believed that the chemotherapy they were receiving was intended to cure them may have made treatment decisions without the full understanding that a cure was not possible. In addition, there was a small subset of patients whose physicians' treatment intent was curative, but the patients believed that their disease was not curable. This type of patient misunderstanding is no less concerning. To our knowledge, this is the first report of pessimistic misunderstanding by patients who are being treated with curative intent.
Of the patient characteristics, patient age predicted non-concordance regarding GOC. This finding is noteworthy in light of other research indicating that providers are more likely to have a frank discussion regarding prognosis with older patients. 12 Our finding that non-native English speakers experienced greater discordance in understanding GOC compared with native English speakers, to our knowledge, has not been documented previously. Finally, our finding that those patients who received printed material were more likely to understand their physicians' treatment intent is also a novel finding. The latter findings suggest that communication between providers and patients is at least a component of the problem. Perhaps longer treatment-planning visits with the inclusion of available friends or family would improve patients' understanding of their disease, its prognosis, and the range of treatment options. Similarly providing communication aids, such as specialized interpreters, may improve understanding of GOC for those with limited English proficiency. [29] [30] [31] [32] [33] The findings may be consistent with low health literacy as a mediating factor. That is, older cancer patients have among the lowest health literacy rates and face complex oncology management options that must balance comorbidities and end-of-life preferences. They may also suffer cognitive and sensory deficits that complicate effective communication. Non-native English speakers also face important barriers to health literacy not only with language proficiency but also with cultural differences that present communication challenges in the health care setting. 34-36 Suboptimal health literacy is an independent risk factor for poor health outcomes, including diminished cancer screening, advanced stage at diagnosis, increased risk of hospitalization, decreased acceptance of and/or compliance with treatment, and decreased participation in clinical trials. 37, 38 The current study does have are some potential limitations. First, the study was conducted at a single institution with few minority patients. Despite this, we had a substantial percentage of study participants for whom English was their second language. Second, we used an original questionnaire to assess communication of GOC information and evaluated patient understanding of GOC with a single question. It is possible that the apparent association between patient receipt of printed material and concordance was confounded by patient literacy. In addition, there was no detailed evaluation or direct observation of what the consent or prognostic discussion between provider and patient entailed. However, the findings suggest that examination of GOC understanding in a larger cohort of patients and examination of potential differences in subsequent health care use according to patient-physician convergence versus nonconvergence regarding GOC are important future steps.
In summary, we demonstrated that only 76% of patients reported GOC that were concordant with the treating oncologist. A 24% rate of cancer patients' misunderstanding about their disease trajectory is consistent with prior research, and most patients deviate toward an optimistic misunderstanding of their prognosis. Our research advances the literature on cancer patients' apparent misunderstanding of the goals of chemotherapy treatment by identifying 2 patient characteristics, age 65 years and non-native English speakers; and these characteristics are associated with a high risk for misunderstanding the goals of chemotherapy treatment. Given that low health literacy may mediate the observed misunderstanding for such patients, longer treatment-planning visits in conjunction with additional communication aids beyond printed materials may be useful to elderly patients and non-native English speaking patients and their physicians when they discuss GOC. Thank you for your assistance. Without the generous cooperation of patients like you, we would not be able to improve our health care delivery system. Please place your completed survey in the envelope provided and a member of the research team will collect the envelope from you today in the infusion suite.
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